MissionIR Articles
-
MissionIRNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Letter to Stockholders
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today released a letter to stockholders from its Chief Executive Officer Dr. James Woody. In the letter, Dr. Woody discussed the company’s continued status to remain…
-
MissionIRNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Collects 2b Disease Trial Data; Receives NASDAQ Notice Regarding Annual Report
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced collection of all patient data for its…
-
MissionIRNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Colleague Receives 2021 International Dupuytren Award
180 Life Sciences Corp. (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced that Dr. Lynn Williams, PhD, has…
-
MissionIRNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) CEO Releases Stockholder Letter
180 Life Sciences Corp. (NASDAQ: ATNF) CEO James Woody, MD, PhD, has issued a letter to ATNF stockholders. In the letter he provides an overview of the company’s activities and accomplishments since his last stockholder…
-
MissionIRNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at Inaugural Emerging Growth Virtual Conference
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it will present at the Inaugural…
-
MissionIRNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Closes on Private Placement with Gross Proceeds of $11.7M
180 Life Sciences Corp. (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced the closing of its previously announced…
-
MissionIRNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at the Biotech Showcase(TM) Digital 2021 Conference
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced…
-
MissionIRNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at LD Micro Main Event
180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today…
-
MissionIRNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Ring Nasdaq Opening Bell
180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Beyond Meat, Inc. (NASDAQ: BYND) Collapse From $14B Darling To Penny Stock Reflects Deeper Structural Issues
- MissionIRNewsBreaks – Xeriant, Inc. (OTCQB: XERI) Advances NEXBOARD(TM) Toward Certification Following Internal Fire Testing
- MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Appoints First Chief Commercial Officer Ahead of Ketamine Launch
- MissionIRNewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Launches NODE-X AI Edge Processor for Drone Threat Detection
- MissionIRNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference